S
Scinai Immunotherapeutics Ltd.
Biotechnology: Biological Products (No Diagnostic Substances) company
Key Metrics of Scinai Immunotherapeutics Ltd.
Revenue—FY 2023
Operating income−$9.7M▲ 12.3% YoY
Net profit−$6.5M▼ 12.1% YoY
Shareholders' equity−$4.6M
Market cap$2.3MSCNI · $0.61
Competitors10identified
About Scinai Immunotherapeutics Ltd.
Sectors
Company details
- Founded
- 2015
- Listed
- Nasdaq: SCNI (since 2015)
Operational Areas of Scinai Immunotherapeutics Ltd.
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameScinai Immunotherapeutics Ltd.
TickerSCNI
ExchangeNasdaq
CountryIsrael
SEC CIK0001611747
Listed since2015
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Website—
US market & SEC filings
SCNI · Nasdaq · SEC CIK 0001611747
Last price · 23 Oct 2026
$0.61
+0.12%
Market cap$2.3M
P/E152.7On FY 2023 diluted EPS
Volume137,846
SectorHealth CareBiotechnology: Biological Products (No Diagnostic Substances)
Country · IPOIsraelListed 2015
SCNI share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Scinai Immunotherapeutics Ltd.
Competitors10identified
Countries2most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | gsk.com | 2022 | United Kingdom | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States | |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.